Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

NGS Targeted Hotspot Panel

CE Marked
Related tests:


EntroGen NGS Targeted Hotspot Panel is a comprehensive 16 gene pan-cancer assay designed to detect clinically relevant hotspot mutations in solid tumors. Utilizing a robust next-generation sequencing (NGS) platform, labs are able to simultaneously analyze several different tumor types by batching up to 12 samples on a single run. NGS Targeted Hotspot Panel (THSP) is compatible with fresh frozen, and formalin fixed paraffin embedded (FFPE) samples. This assay features high sensitivity and throughput detecting clinically relevant hotspot variants down to 5% with minimal DNA input. With its comprehensive, streamlined workflow, THSP is designed to be seamlessly integrated into any lab. Laboratories with specific challenges, such as low disease specific sample volumes, are able to batch various sample types together and accelerate tumor profiling.
Acute Myelogenous Leukemia, Bladder Cancer, Breast Cancer, CNS Tumor, Colorectal Cancer, Gastrointestinal Stromal Tumor, Glioma, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer, Thyroid Gland Carcinoma
BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
See More ...
Next-Generation Sequencing (NGS)